Crohn’s & Colitis Congress (CCC 2026)

A novel therapeutic approach combining behavioural and biologic treatments appears feasible for the management of individuals with Crohn’s disease, based on feasibility and early outcomes from the CATHARSIS* trial.

Treatment with upadacitinib appears to yield high and durable remission rates in patients with ulcerative colitis (UC), according to 1-year data from a real-world study.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with inflammatory bowel disease (IBD) appears to result in favourable clinical outcomes, as shown in two retrospective studies.

Exposure to advanced therapies, including biologics and small molecules, within 3 months of conception is not associated with an increase in time to pregnancy among women with inflammatory bowel disease (IBD), according to the WIsDoM* trial presented at the Crohn’s and Colitis Congress 2026.

Treatment with mirikizumab results in significant improvements in clinical, endoscopic, and histologic outcomes during induction and maintenance phases in patients with Crohn’s disease (CD) or ulcerative colitis (UC), according to an updated meta-analysis of randomized controlled trials (RCTs).

Treatment with either vedolizumab or ustekinumab delivers significant and meaningful benefits to patients with Crohn’s disease (CD), but each has its distinct therapeutic profile with complementary advantages, reports a real-world study presented at CCC 2026.